Obesity is a severe public health problem, contributing to the global non-communicable disease burden, including type 2 diabetes (T2D), cardiovascular disease (CVD), and metabolic syndrome. A threefold increase in obesity and overweight has been reported since 1975 and is predicted to affect 1 billion adults (almost 20% of the world’s population) by 2025 if current trends continue.
Advances in treatment include bariatric surgery, pharmacological intervention with significant weight loss outcomes, and less highlighted being combination therapies for weight loss. Many monotherapies are modestly efficacious, with side effects at high clinical doses. Combination therapies such as low-dose phentermine and sustained release topiramate and naltrexone/bupropion and others offer alternative possibilities as they target different central or peripheral mechanisms.
This Research Topic aims to explore possible and viable combination therapies for weight loss and management for obesity and related metabolic syndrome.
Studies employing animal models, clinical trials and review articles are welcome:
• CNS system mechanisms and research targets
• Peripheral mechanisms and research targets
• Pharmacological treatments for obesity and metabolic syndrome
Keywords:
Obesity, Metabolic syndrome, Combination Therapeutics, Targets
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
Obesity is a severe public health problem, contributing to the global non-communicable disease burden, including type 2 diabetes (T2D), cardiovascular disease (CVD), and metabolic syndrome. A threefold increase in obesity and overweight has been reported since 1975 and is predicted to affect 1 billion adults (almost 20% of the world’s population) by 2025 if current trends continue.
Advances in treatment include bariatric surgery, pharmacological intervention with significant weight loss outcomes, and less highlighted being combination therapies for weight loss. Many monotherapies are modestly efficacious, with side effects at high clinical doses. Combination therapies such as low-dose phentermine and sustained release topiramate and naltrexone/bupropion and others offer alternative possibilities as they target different central or peripheral mechanisms.
This Research Topic aims to explore possible and viable combination therapies for weight loss and management for obesity and related metabolic syndrome.
Studies employing animal models, clinical trials and review articles are welcome:
• CNS system mechanisms and research targets
• Peripheral mechanisms and research targets
• Pharmacological treatments for obesity and metabolic syndrome
Keywords:
Obesity, Metabolic syndrome, Combination Therapeutics, Targets
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.